FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to ophthalmology and can be used in treating retinopathy in prematurity or related retinopathic diseases. That is ensured by the introduction into the retina of an effective number of differential antigen negative hematopoietic stem cell population. Such stem cell population represents a population recovered from myeloid-like marrow cells in which the most part of cells is differential antigen negative and expresses CD44 antigen and CD11b antigen.
EFFECT: method allows to provide physiological revascularisation in the damaged retinal regions and to relieve the invoked retinal damages due to the expression of antigens exhibiting high vasotrophic activity.
16 cl, 3 tbl, 36 dwg, 14 ex
